Enovis Corporation (ENOV)

US — Industrials Sector
Peers: HLIO  NPO  OFLX  LXFR  HURC  IEX  WTS  DCI  GRC  EPAC  MIDD  KAI  ITT  FELE  GHM 

Automate Your Wheel Strategy on ENOV

With Tiblio's Option Bot, you can configure your own wheel strategy including ENOV - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ENOV
  • Rev/Share 37.8609
  • Book/Share 46.1372
  • PB 0.6532
  • Debt/Equity 0.5573
  • CurrentRatio 2.5516
  • ROIC -0.1754

 

  • MktCap 1719973530.0
  • FreeCF/Share -0.6864
  • PFCF -44.12
  • PE -2.1125
  • Debt/Assets 0.2993
  • DivYield 0
  • ROE -0.2745

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 5
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation ENOV JMP Securities -- Mkt Outperform -- $62 Oct. 3, 2024

News

Enovis (ENOV) Q1 Earnings and Revenues Surpass Estimates
ENOV
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive

Enovis (ENOV) came out with quarterly earnings of $0.81 per share, beating the Zacks Consensus Estimate of $0.74 per share. This compares to earnings of $0.50 per share a year ago.

Read More
image for news Enovis (ENOV) Q1 Earnings and Revenues Surpass Estimates
Enovis Announces First Quarter 2025 Results
ENOV
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral

Continued commercial momentum with first-quarter sales growth of 8% on a reported basis and strong adjusted EBITDA margin expansion First-quarter Reconstructive sales grew 11% year-over-year on a reported basis Appointed Damien McDonald as CEO, effective May 12 th , 2025 Wilmington, DE, May 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the first quarter ended April 4, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET.

Read More
image for news Enovis Announces First Quarter 2025 Results
Enovis™ to Exhibit Extensive Range of Foot & Ankle Solutions at ACFAS 2025
ENOV
Published: March 25, 2025 by: GlobeNewsWire
Sentiment: Neutral

WILMINGTON, DE, March 25, 2025 (GLOBE NEWSWIRE) -- Enovis™ (NYSE: ENOV), a global medical technology innovator, will feature its expanding portfolio of foot and ankle solutions at this year's American College of Foot & Ankle Surgeons (ACFAS) Annual Scientific Conference in Phoenix, Ariz., taking place March 27-30.

Read More
image for news Enovis™ to Exhibit Extensive Range of Foot & Ankle Solutions at ACFAS 2025
Enovis Corporation (ENOV) Q4 2024 Earnings Call Transcript
ENOV
Published: February 26, 2025 by: Seeking Alpha
Sentiment: Neutral

Enovis Corporation (NYSE:ENOV ) Q4 2024 Results Conference Call February 26, 2025 8:30 AM ET Company Participants Kyle Rose - Vice President of Investor Relations Matt Trerotola - CEO & Chairman Ben Berry - Senior VP & CFO Conference Call Participants Vic Chopra - Wells Fargo Vijay Kumar - Evercore ISI Robbie Marcus - JPMorgan Jeff Johnson - Baird Brandon Vazquez - William Blair Danielle Antalffy - UBS Mike Matson - Needham & Company Caitlin Cronin - Canaccord Jason Wittes - ROTH Operator Good day, and welcome to the Enovis Fourth Quarter 2024 Earnings Conference Call. All participants will be …

Read More
image for news Enovis Corporation (ENOV) Q4 2024 Earnings Call Transcript
Enovis Announces Fourth Quarter and Full Year 2024 Results
ENOV
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral

Wilmington, DE, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the fourth quarter and full year ended December 31, 2024. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET.

Read More
image for news Enovis Announces Fourth Quarter and Full Year 2024 Results
Enovis Announces Planned CEO Succession Process
ENOV
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral

Wilmington, DE, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), a leader in medical technology innovation, announced today that Matt Trerotola has informed the Board of Directors (the “Board”) of his intention to retire from his position as Chief Executive Officer (CEO) of Enovis, effective upon his successor being appointed by the Board and assuming the position as CEO. As part of the Company's succession planning process, the Board is actively working with an executive search firm to identify a growth-oriented MedTech leader who shares our passion for continuous improvement and patient outcomes, to …

Read More
image for news Enovis Announces Planned CEO Succession Process

About Enovis Corporation (ENOV)

  • IPO Date 2008-05-08
  • Website https://www.enovis.com
  • Industry Industrial - Machinery
  • CEO Mr. Damien McDonald
  • Employees 7367

Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.